Free Trial
→ First Look: Elon’s “Starphone” (From Stansberry Research) (Ad)tc pixel Free BBNX Stock Alerts

Beta Bionics (BBNX) Financials

Beta Bionics logo
$17.63 +0.20 (+1.15%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$17.70 +0.07 (+0.37%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Beta Bionics

Annual Income Statements for Beta Bionics

This table shows Beta Bionics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -44 -55 -73
Consolidated Net Income / (Loss)		 -44 -55 -73
Net Income / (Loss) Continuing Operations		 -44 -55 -73
Total Pre-Tax Income 		-44 -55 -73
Total Operating Income		 -36 -45 -72
Total Gross Profit		 6.31 36 56
Total Revenue		 12 65 100
Operating Revenue		 12 65 100
Total Cost of Revenue		 5.69 29 45
Operating Cost of Revenue		 5.69 29 45
Total Operating Expenses		 42 81 127
Selling, General & Admin Expense		 12 18 31
Marketing Expense		 12 37 61
Research & Development Expense		 18 26 35
Total Other Income / (Expense), net		 -8.25 -9.50 -1.52
Interest & Investment Income		 1.78 3.91 11
Other Income / (Expense), net		 -10 -13 -12
Basic Earnings per Share		 ($8.31) ($8.60) ($1.81)
Weighted Average Basic Shares Outstanding		 5.30M 6.37M 40.53M
Diluted Earnings per Share		 ($8.31) ($8.60) ($1.81)
Weighted Average Diluted Shares Outstanding		 5.30M 6.37M 40.53M
Weighted Average Basic & Diluted Shares Outstanding		 - 43.35M 44.38M

Quarterly Income Statements for Beta Bionics

This table shows Beta Bionics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22 -23
Consolidated Net Income / (Loss)		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22 -23
Net Income / (Loss) Continuing Operations		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22 -23
Total Pre-Tax Income 		-12 -14 -9.74 -18 -29 -17 -14 -13 -22 -23
Total Operating Income		 -9.45 -12 -11 -13 -19 -20 -17 -16 -24 -26
Total Gross Profit		 7.20 8.08 8.91 12 8.97 13 15 19 16 19
Total Revenue		 13 15 17 20 18 23 27 32 28 32
Operating Revenue		 13 15 17 20 18 23 27 32 28 32
Total Cost of Revenue		 5.73 6.96 7.79 8.75 8.67 11 12 13 11 13
Operating Cost of Revenue		 5.73 6.96 7.79 8.75 8.67 11 12 13 11 13
Total Operating Expenses		 17 20 20 25 28 32 32 35 41 44
Selling, General & Admin Expense		 3.51 4.54 5.11 4.71 6.62 7.88 7.92 8.60 9.62 9.60
Marketing Expense		 7.66 8.97 9.65 11 13 16 16 16 21 25
Research & Development Expense		 5.48 6.35 5.14 9.21 7.59 8.87 8.20 10 10 10
Total Other Income / (Expense), net		 -3.00 -2.68 1.24 -5.07 -10 3.00 2.83 2.66 2.38 2.18
Interest & Investment Income		 1.14 0.99 0.83 0.95 2.44 3.01 2.83 2.66 2.38 2.18
Other Income / (Expense), net		 -4.14 -3.67 0.42 -6.02 -12 -0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($2.07) ($2.37) ($1.46) ($2.70) ($0.93) ($0.39) ($0.33) ($0.16) ($0.49) ($0.53)
Weighted Average Basic Shares Outstanding		 6.02M 6.11M 6.66M 6.37M 30.71M 43.39M 43.63M 40.53M 44.44M 44.55M
Diluted Earnings per Share		 ($2.07) ($2.37) ($1.46) ($2.70) ($0.93) ($0.39) ($0.33) ($0.16) ($0.49) ($0.53)
Weighted Average Diluted Shares Outstanding		 6.02M 6.11M 6.66M 6.37M 30.71M 43.39M 43.63M 40.53M 44.44M 44.55M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 43.35M 43.36M 43.47M 44.02M 44.38M 44.56M 44.99M

Annual Cash Flow Statements for Beta Bionics

This table details how cash moves in and out of Beta Bionics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -1.11 3.87 1.14
Net Cash From Operating Activities		 -32 -48 -51
Net Cash From Continuing Operating Activities		 -32 -48 -51
Net Income / (Loss) Continuing Operations		 -44 -55 -73
Consolidated Net Income / (Loss)		 -44 -55 -73
Depreciation Expense		 1.23 1.15 1.57
Amortization Expense		 0.87 1.13 1.37
Non-Cash Adjustments To Reconcile Net Income		 13 16 28
Changes in Operating Assets and Liabilities, net		 -3.22 -12 -8.99
Net Cash From Investing Activities		 -70 -3.48 -163
Net Cash From Continuing Investing Activities		 -70 -3.48 -163
Purchase of Property, Plant & Equipment		 -0.40 -3.40 -5.30
Purchase of Investments		 -69 -72 -328
Sale of Property, Plant & Equipment		 0.00 0.05 0.00
Sale and/or Maturity of Investments		 0.00 72 170
Net Cash From Financing Activities		 101 56 215
Net Cash From Continuing Financing Activities		 101 56 215
Repurchase of Common Equity		 0.00 -4.15 0.00
Issuance of Preferred Equity		 101 60 0.00
Issuance of Common Equity		 - 0.00 210
Other Financing Activities, net		 0.03 0.10 4.76

Quarterly Cash Flow Statements for Beta Bionics

This table details how cash moves in and out of Beta Bionics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -4.49 -9.04 4.45 13 12 -7.38 3.41 -6.91 -1.37 14
Net Cash From Operating Activities		 -12 -12 -9.61 -14 -20 -14 -8.73 -8.63 -24 -15
Net Cash From Continuing Operating Activities		 -12 -12 -9.61 -14 -20 -14 -8.73 -8.63 -24 -15
Net Income / (Loss) Continuing Operations		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22 -23
Consolidated Net Income / (Loss)		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22 -23
Depreciation Expense		 0.29 0.30 0.33 0.23 0.30 0.35 0.39 0.54 0.59 0.71
Amortization Expense		 0.28 0.28 0.28 0.30 -0.62 0.31 0.30 0.46 0.49 0.50
Non-Cash Adjustments To Reconcile Net Income		 4.62 4.34 1.21 6.18 15 4.12 4.48 5.18 5.41 7.03
Changes in Operating Assets and Liabilities, net		 -4.88 -2.69 -1.71 -2.88 -6.47 -1.50 0.32 -1.34 -8.21 0.51
Net Cash From Investing Activities		 7.64 3.30 15 -30 -179 6.17 9.49 0.66 22 27
Net Cash From Continuing Investing Activities		 7.64 3.30 15 -30 -179 6.17 9.49 0.66 22 27
Purchase of Property, Plant & Equipment		 -0.41 -0.51 -1.92 -0.56 -0.33 -1.78 -1.28 -1.90 -1.38 -1.04
Purchase of Investments		 0.00 -20 -6.84 -45 -207 -15 -60 -45 -25 -20
Sale and/or Maturity of Investments		 8.00 24 24 16 28 23 71 48 48 48
Net Cash From Financing Activities		 0.01 -0.11 -1.18 57 211 0.04 2.65 1.06 0.62 1.80
Net Cash From Continuing Financing Activities		 0.01 -0.11 -1.18 57 211 0.04 2.65 1.06 0.62 1.80
Issuance of Common Equity		 0.00 - - - 211 - - -0.90 0.00 2.42
Other Financing Activities, net		 0.01 0.01 0.05 0.04 0.10 0.04 2.65 1.96 0.62 -0.62

Annual Balance Sheets for Beta Bionics

This table presents Beta Bionics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 110 150 329
Total Current Assets		 104 133 268
Cash & Equivalents		 27 30 32
Restricted Cash		 - 0.00 0.10
Short-Term Investments		 70 73 188
Accounts Receivable		 4.45 12 17
Inventories, net		 1.25 13 22
Prepaid Expenses		 1.18 4.03 9.84
Plant, Property, & Equipment, net		 2.48 4.78 8.60
Total Noncurrent Assets		 3.94 12 52
Long-Term Investments		 - 0.00 45
Other Noncurrent Operating Assets		 3.94 12 6.81
Total Liabilities & Shareholders' Equity		 110 150 329
Total Liabilities		 51 74 41
Total Current Liabilities		 11 21 31
Accounts Payable		 1.17 2.85 5.00
Accrued Expenses		 8.13 16 22
Current Deferred Revenue		 0.09 0.94 1.56
Other Current Liabilities		 1.22 1.53 1.94
Total Noncurrent Liabilities		 41 52 10
Capital Lease Obligations		 3.00 5.73 5.37
Noncurrent Deferred Revenue		 0.26 1.86 3.30
Other Noncurrent Operating Liabilities		 38 45 1.55
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -203 -245 288
Total Preferred & Common Equity		 -203 -245 288
Preferred Stock		 - 0.00 0.00
Total Common Equity		 -203 -245 288
Common Stock		 26 51 657
Retained Earnings		 -230 -297 -370
Accumulated Other Comprehensive Income / (Loss)		 0.14 0.07 0.40

Quarterly Balance Sheets for Beta Bionics

This table presents Beta Bionics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 338 330 330 304 292
Total Current Assets		 262 286 270 248 231
Cash & Equivalents		 42 35 38 30 44
Restricted Cash		 - - - 0.10 0.10
Short-Term Investments		 189 215 190 169 136
Accounts Receivable		 9.06 11 12 16 18
Inventories, net		 16 17 20 24 24
Prepaid Expenses		 5.65 7.64 9.43 8.89 8.47
Plant, Property, & Equipment, net		 5.52 6.47 7.39 10 11
Total Noncurrent Assets		 71 37 53 46 51
Long-Term Investments		 64 31 45 40 45
Other Noncurrent Operating Assets		 6.59 6.28 7.31 6.41 5.96
Total Liabilities & Shareholders' Equity		 338 330 330 304 292
Total Liabilities		 24 28 35 33 36
Total Current Liabilities		 16 19 25 23 26
Accounts Payable		 3.45 3.42 4.46 2.32 5.35
Accrued Expenses		 11 13 18 17 17
Current Deferred Revenue		 0.95 1.14 1.34 1.71 1.88
Other Current Liabilities		 1.52 1.52 1.98 1.84 1.59
Total Noncurrent Liabilities		 7.78 8.85 9.90 9.98 10
Capital Lease Obligations		 5.45 5.17 5.71 5.07 4.92
Noncurrent Deferred Revenue		 2.33 2.67 2.99 3.35 3.45
Other Noncurrent Operating Liabilities		 0.00 1.01 1.21 1.56 1.63
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 314 302 295 271 256
Total Preferred & Common Equity		 314 302 295 271 256
Preferred Stock		 0.00 0.00 0.00 - 0.00
Total Common Equity		 314 302 295 271 256
Common Stock		 639 644 651 663 672
Retained Earnings		 -325 -342 -356 -392 -415
Accumulated Other Comprehensive Income / (Loss)		 0.24 0.15 0.35 -0.10 -0.39

Annual Metrics And Ratios for Beta Bionics

This table displays calculated financial ratios and metrics derived from Beta Bionics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - 44,024,631.00
DEI Adjusted Shares Outstanding		 - - 44,024,631.00
DEI Earnings Per Adjusted Shares Outstanding		 - - -1.66
Growth Metrics		 - - -
Revenue Growth		 0.00% 442.93% 53.94%
EBITDA Growth		 0.00% -28.77% -44.01%
EBIT Growth		 0.00% -27.88% -43.41%
NOPAT Growth		 0.00% -26.22% -58.41%
Net Income Growth		 0.00% -24.17% -33.68%
EPS Growth		 0.00% -3.49% 78.95%
Operating Cash Flow Growth		 0.00% -48.78% -5.49%
Free Cash Flow Firm Growth		 0.00% 0.00% -123.07%
Invested Capital Growth		 0.00% 37.86% 229.69%
Revenue Q/Q Growth		 0.00% 0.00% 13.19%
EBITDA Q/Q Growth		 0.00% 0.00% 4.02%
EBIT Q/Q Growth		 0.00% 0.00% 3.37%
NOPAT Q/Q Growth		 0.00% 0.00% -4.50%
Net Income Q/Q Growth		 0.00% 0.00% 5.96%
EPS Q/Q Growth		 0.00% 0.00% 58.39%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 9.99%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 7.06%
Profitability Metrics		 - - -
Gross Margin		 52.59% 55.11% 55.40%
EBITDA Margin		 -365.03% -86.58% -80.99%
Operating Margin		 -298.87% -69.48% -71.50%
EBIT Margin		 -382.46% -90.08% -83.92%
Profit (Net Income) Margin		 -367.64% -84.08% -73.02%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 96.13% 93.34% 87.01%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -1,547.95%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -1,535.05%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 1,507.69%
Return on Equity (ROE)		 -75.24% -81.35% -40.26%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -354.29%
Operating Return on Assets (OROA)		 -41.69% -45.18% -35.17%
Return on Assets (ROA)		 -40.08% -42.17% -30.60%
Return on Common Equity (ROCE)		 260.76% 271.00% -4.68%
Return on Equity Simple (ROE_SIMPLE)		 21.71% 22.32% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -32 -50
NOPAT Margin		 -209.21% -48.64% -50.05%
Net Nonoperating Expense Percent (NNEP)		 -20.27% -24.09% -12.89%
Return On Investment Capital (ROIC_SIMPLE)		 12.54% 13.22% -17.13%
Cost of Revenue to Revenue		 47.41% 44.89% 44.60%
SG&A Expenses to Revenue		 101.92% 27.44% 30.95%
R&D to Revenue		 149.59% 40.21% 34.70%
Operating Expenses to Revenue		 351.46% 124.59% 126.90%
Earnings before Interest and Taxes (EBIT)		 -46 -59 -84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -56 -81
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 0.00 4.29
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.29
Price to Revenue (P/Rev)		 17.01 3.13 12.32
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 34.45
Enterprise Value to Revenue (EV/Rev)		 31.01 6.56 9.73
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.05 0.08 0.02
Long-Term Debt to Equity		 0.05 0.08 0.02
Financial Leverage		 -1.60 -1.42 -0.98
Leverage Ratio		 1.88 1.93 1.32
Compound Leverage Factor		 1.80 1.80 1.14
Debt to Total Capital		 4.87% 7.01% 1.83%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.87% 7.01% 1.83%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 424.81% 393.17% 0.00%
Common Equity to Total Capital		 -329.68% -300.17% 98.17%
Debt to EBITDA		 -0.07 -0.10 -0.07
Net Debt to EBITDA		 2.14 1.74 3.19
Long-Term Debt to EBITDA		 -0.07 -0.10 -0.07
Debt to NOPAT		 -0.12 -0.18 -0.11
Net Debt to NOPAT		 3.74 3.09 5.17
Long-Term Debt to NOPAT		 -0.12 -0.18 -0.11
Altman Z-Score		 -0.79 -1.08 16.76
Noncontrolling Interest Sharing Ratio		 446.55% 433.13% 88.38%
Liquidity Ratios		 - - -
Current Ratio		 9.77 6.29 8.66
Quick Ratio		 9.54 5.46 7.64
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -45 -100
Operating Cash Flow to CapEx		 -8,152.01% -1,443.14% -961.39%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.11 0.50 0.42
Accounts Receivable Turnover		 2.70 7.92 6.89
Inventory Turnover		 4.57 4.01 2.55
Fixed Asset Turnover		 4.84 17.96 14.99
Accounts Payable Turnover		 4.88 14.55 11.39
Days Sales Outstanding (DSO)		 135.35 46.08 53.00
Days Inventory Outstanding (DIO)		 79.91 90.92 143.02
Days Payable Outstanding (DPO)		 74.84 25.08 32.04
Cash Conversion Cycle (CCC)		 140.42 111.92 163.98
Capital & Investment Metrics		 - - -
Invested Capital		 -35 -22 28
Invested Capital Turnover		 -0.34 -2.29 30.93
Increase / (Decrease) in Invested Capital		 0.00 13 50
Enterprise Value (EV)		 372 428 976
Market Capitalization		 204 204 1,235
Book Value per Share		 ($38.30) ($38.55) $6.53
Tangible Book Value per Share		 ($38.30) ($38.55) $6.53
Total Capital		 62 82 293
Total Debt		 3.00 5.73 5.37
Total Long-Term Debt		 3.00 5.73 5.37
Net Debt		 -94 -98 -259
Capital Expenditures (CapEx)		 0.40 3.35 5.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.73 8.20 18
Debt-free Net Working Capital (DFNWC)		 93 112 237
Net Working Capital (NWC)		 93 112 237
Net Nonoperating Expense (NNE)		 19 23 23
Net Nonoperating Obligations (NNO)		 -94 -98 -259
Total Depreciation and Amortization (D&A)		 2.09 2.28 2.94
Debt-free, Cash-free Net Working Capital to Revenue		 -31.09% 12.59% 17.71%
Debt-free Net Working Capital to Revenue		 775.46% 171.63% 236.39%
Net Working Capital to Revenue		 775.46% 171.63% 236.39%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($8.60) ($1.81)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 6.37M 40.53M
Adjusted Diluted Earnings per Share		 $0.00 ($8.60) ($1.81)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 6.37M 40.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 43.35M 44.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -32 -50
Normalized NOPAT Margin		 -209.21% -48.64% -50.05%
Pre Tax Income Margin		 -367.64% -84.08% -73.02%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -7.57% 0.00%

Quarterly Metrics And Ratios for Beta Bionics

This table displays calculated financial ratios and metrics derived from Beta Bionics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - 0.00 - - - 44,024,631.00 44,382,146.00 44,561,695.00
DEI Adjusted Shares Outstanding		 - - - 0.00 - - - 44,024,631.00 44,382,146.00 44,561,695.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - 0.00 - - - -0.31 -0.49 -0.53
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 36.39% 54.45% 63.14% 57.15% 56.62% 37.76%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% -134.07% -29.17% -64.46% 18.37% 26.13% -21.61%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% -128.82% -28.58% -61.35% 15.40% 21.94% -28.70%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% -97.21% -68.64% -55.26% -23.68% -30.20% -28.71%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% -130.19% -16.64% -45.94% 25.64% 23.59% -38.73%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 55.07% 83.54% 77.40% 94.07% 47.31% -35.90%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -64.48% -11.09% 9.20% 39.58% -19.31% -7.56%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18.16% 29.67%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 229.69% 55.25% 39.02%
Revenue Q/Q Growth		 0.00% 16.34% 11.03% 22.36% 0.00% 31.74% 17.28% 17.86% -13.99% 15.88%
EBITDA Q/Q Growth		 0.00% -14.24% 33.15% -86.27% 0.00% 36.96% 14.89% 7.54% -53.38% -5.03%
EBIT Q/Q Growth		 0.00% -13.75% 31.66% -80.43% 0.00% 36.08% 14.25% 5.39% -50.54% -5.39%
NOPAT Q/Q Growth		 0.00% -24.66% 6.85% -18.77% 0.00% -6.60% 14.24% 5.39% -50.53% -5.39%
Net Income Q/Q Growth		 0.00% -16.18% 32.68% -85.99% 0.00% 41.13% 15.77% 5.23% -62.59% -6.89%
EPS Q/Q Growth		 0.00% -14.49% 38.40% -84.93% 0.00% 58.06% 15.38% 51.52% -206.25% -8.16%
Operating Cash Flow Q/Q Growth		 0.00% -0.77% 21.44% -48.54% 0.00% 31.94% 35.79% 1.17% -176.25% 38.65%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -8.34% 3.67% -60.08% 51.01% 6.89%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 9.30% 2.01% 7.06% 30.06% -2.13%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 55.68% 53.73% 53.36% 57.19% 50.86% 53.80% 55.48% 58.98% 59.50% 59.04%
EBITDA Margin		 -100.71% -98.90% -59.55% -90.65% -172.84% -82.71% -60.03% -47.09% -83.97% -76.11%
Operating Margin		 -73.09% -78.32% -65.71% -63.78% -105.69% -85.52% -62.54% -50.20% -87.86% -79.90%
EBIT Margin		 -105.06% -102.73% -63.23% -93.23% -176.27% -85.52% -62.53% -50.19% -87.86% -79.90%
Profit (Net Income) Margin		 -96.26% -96.13% -58.28% -88.59% -162.46% -72.59% -52.14% -41.92% -79.26% -73.10%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.01% 100.00% 100.00% 100.00% 100.01% 100.00% 100.01%
Interest Burden Percent		 91.62% 93.58% 92.18% 95.01% 92.17% 84.88% 83.38% 83.51% 90.21% 91.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -435.49% -360.21% -293.15% -1,086.74% -223.90% -214.78%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -424.73% -358.06% -291.45% -1,085.52% -222.03% -212.56%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 392.62% 327.28% 265.30% 1,066.16% 199.05% 188.95%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -81.35% -42.88% -32.93% -27.85% -20.57% -24.86% -25.83%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -354.29% -222.02% -220.16%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -46.76% -36.41% -20.22% -16.78% -21.04% -30.15% -30.56%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -44.43% -33.56% -17.16% -13.99% -17.57% -27.20% -27.96%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 271.00% -42.88% -32.93% -27.85% -2.39% -24.86% -25.83%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% -22.62% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.62 -8.25 -7.68 -9.13 -13 -14 -12 -11 -17 -18
NOPAT Margin		 -51.16% -54.82% -46.00% -44.65% -73.98% -59.86% -43.78% -35.14% -61.50% -55.93%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -9.18% -10.76% -2.15% -1.70% -1.22% -1.87% -2.22%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 3.81% -4.09% -4.53% -3.97% -3.85% -6.15% -6.85%
Cost of Revenue to Revenue		 44.32% 46.27% 46.64% 42.81% 49.14% 46.20% 44.52% 41.02% 40.50% 40.96%
SG&A Expenses to Revenue		 27.16% 30.20% 30.56% 23.03% 37.54% 33.91% 29.07% 26.78% 34.81% 29.99%
R&D to Revenue		 42.36% 42.20% 30.78% 45.08% 43.03% 38.18% 30.07% 31.54% 37.49% 31.99%
Operating Expenses to Revenue		 128.77% 132.05% 119.07% 120.97% 156.55% 139.32% 118.01% 109.17% 147.35% 138.94%
Earnings before Interest and Taxes (EBIT)		 -14 -15 -11 -19 -31 -20 -17 -16 -24 -26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -15 -9.95 -19 -30 -19 -16 -15 -23 -24
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 1.20 2.09 2.94 4.29 1.64 2.72
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 1.20 2.09 2.94 4.29 1.64 2.72
Price to Revenue (P/Rev)		 0.00 0.00 0.00 3.13 5.38 8.10 9.79 12.32 4.04 5.87
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 3.62 13.73 22.63 34.45 5.72 13.25
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 6.56 1.23 4.56 6.76 9.73 1.91 4.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.08 0.02 0.02 0.02 0.02 0.02 0.02
Long-Term Debt to Equity		 0.00 0.00 0.00 0.08 0.02 0.02 0.02 0.02 0.02 0.02
Financial Leverage		 0.00 0.00 0.00 -1.29 -0.92 -0.91 -0.91 -0.98 -0.90 -0.89
Leverage Ratio		 0.00 0.00 0.00 1.93 1.08 1.09 1.12 1.32 1.10 1.12
Compound Leverage Factor		 0.00 0.00 0.00 1.83 0.99 0.93 0.93 1.10 0.99 1.02
Debt to Total Capital		 0.00% 0.00% 0.00% 7.01% 1.71% 1.68% 1.90% 1.83% 1.84% 1.88%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 7.01% 1.71% 1.68% 1.90% 1.83% 1.84% 1.88%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 393.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% -300.17% 98.29% 98.32% 98.10% 98.17% 98.16% 98.12%
Debt to EBITDA		 0.00 0.00 0.00 -0.10 -0.07 -0.07 -0.07 -0.07 -0.07 -0.06
Net Debt to EBITDA		 0.00 0.00 0.00 1.74 3.93 3.53 3.17 3.19 3.21 2.85
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.10 -0.07 -0.07 -0.07 -0.07 -0.07 -0.06
Debt to NOPAT		 0.00 0.00 0.00 -0.18 -0.14 -0.12 -0.12 -0.11 -0.09 -0.08
Net Debt to NOPAT		 0.00 0.00 0.00 3.09 7.61 6.30 5.59 5.17 4.33 3.79
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.18 -0.14 -0.12 -0.12 -0.11 -0.09 -0.08
Altman Z-Score		 0.00 0.00 0.00 -0.20 8.72 12.93 14.22 17.45 7.24 10.60
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 433.13% 0.00% 0.00% 0.00% 88.38% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 6.29 15.88 14.68 10.64 8.66 10.69 8.88
Quick Ratio		 0.00 0.00 0.00 5.46 14.58 13.40 9.46 7.64 9.28 7.63
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 -37 -40 -38 -61 -30 -28
Operating Cash Flow to CapEx		 -3,411.24% -2,413.61% -500.42% -2,545.28% -5,998.50% -764.14% -680.89% -453.34% -1,730.72% -1,407.31%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.50 0.21 0.24 0.27 0.42 0.34 0.38
Accounts Receivable Turnover		 0.00 0.00 0.00 7.92 7.71 6.85 7.68 6.89 8.89 8.08
Inventory Turnover		 0.00 0.00 0.00 4.01 2.05 2.08 1.98 2.55 2.39 2.41
Fixed Asset Turnover		 0.00 0.00 0.00 17.96 12.66 12.07 11.99 14.99 14.07 13.83
Accounts Payable Turnover		 0.00 0.00 0.00 14.55 9.31 10.50 9.03 11.39 16.37 11.31
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 46.08 47.36 53.31 47.55 53.00 41.07 45.16
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 90.92 178.46 175.90 184.57 143.02 152.45 151.71
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 25.08 39.19 34.77 40.42 32.04 22.30 32.28
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 111.92 186.63 194.44 191.71 163.98 171.22 164.59
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -22 24 26 26 28 37 36
Invested Capital Turnover		 0.00 0.00 0.00 -2.98 5.89 6.02 6.70 30.93 3.64 3.84
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 24 26 26 50 13 10
Enterprise Value (EV)		 0.00 0.00 0.00 428 86 356 599 976 211 478
Market Capitalization		 204 204 204 204 376 632 867 1,235 445 698
Book Value per Share		 $0.00 $0.00 $0.00 ($38.55) $7.24 $6.96 $6.78 $6.53 $6.11 $5.75
Tangible Book Value per Share		 $0.00 $0.00 $0.00 ($38.55) $7.24 $6.96 $6.78 $6.53 $6.11 $5.75
Total Capital		 0.00 0.00 0.00 82 319 307 300 293 276 261
Total Debt		 0.00 0.00 0.00 5.73 5.45 5.17 5.71 5.37 5.07 4.92
Total Long-Term Debt		 0.00 0.00 0.00 5.73 5.45 5.17 5.71 5.37 5.07 4.92
Net Debt		 0.00 0.00 0.00 -98 -290 -276 -268 -259 -234 -220
Capital Expenditures (CapEx)		 0.36 0.51 1.92 0.56 0.33 1.78 1.28 1.90 1.38 1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 8.20 14 17 16 18 25 24
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 112 245 267 245 237 225 205
Net Working Capital (NWC)		 0.00 0.00 0.00 112 245 267 245 237 225 205
Net Nonoperating Expense (NNE)		 5.83 6.21 2.05 8.98 16 2.96 2.28 2.18 4.91 5.50
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -98 -290 -276 -268 -259 -234 -220
Total Depreciation and Amortization (D&A)		 0.56 0.58 0.62 0.53 0.60 0.65 0.68 1.00 1.07 1.21
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 12.59% 19.98% 21.62% 18.01% 17.71% 22.84% 20.53%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 171.63% 351.46% 341.68% 276.21% 236.39% 203.92% 172.26%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 171.63% 351.46% 341.68% 276.21% 236.39% 203.92% 172.26%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($2.70) ($0.93) ($0.39) ($0.33) ($0.16) ($0.49) ($0.53)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 6.37M 30.71M 43.39M 43.63M 40.53M 44.44M 44.55M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.70) ($0.93) ($0.39) ($0.33) ($0.16) ($0.49) ($0.53)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 6.37M 30.71M 43.39M 43.63M 40.53M 44.44M 44.55M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 43.35M 43.36M 43.47M 44.02M 44.38M 44.56M 44.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.62 -8.25 -7.68 -9.13 -13 -14 -12 -11 -17 -18
Normalized NOPAT Margin		 -51.16% -54.82% -46.00% -44.65% -73.98% -59.86% -43.78% -35.14% -61.50% -55.93%
Pre Tax Income Margin		 -96.26% -96.13% -58.28% -88.58% -162.46% -72.59% -52.14% -41.92% -79.26% -73.10%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -7.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Beta Bionics’ financial results show strong revenue growth, but the company remains unprofitable and continues to consume cash. Quarterly revenue increased from $12.9 million in Q1 2024 to $32.0 million in Q2 2026. Revenue also rose 15.9% from Q1 2026, although the latest quarter was roughly flat compared with Q4 2025.

  • Revenue growth remains a key strength. Q2 2026 revenue of $32.0 million was approximately 38% higher than Q2 2025 and more than double Q1 2024 revenue.
  • Gross margins have improved. Gross profit was $18.9 million in Q2 2026, representing a margin of approximately 59%, compared with about 54% in Q2 2025 and 56% in Q4 2024.
  • Liquidity remains strong relative to current obligations. Beta Bionics reported $44.3 million of cash, $136.2 million of short-term investments and $44.6 million of long-term investments at June 30, 2026. Total liabilities were $36.0 million, giving the company substantial financial flexibility.
  • Operating cash outflow improved sequentially. Cash used in operating activities declined to $14.6 million in Q2 2026 from $23.8 million in Q1 2026, although it remained negative.
  • Investment portfolio activity supported cash balances. Beta Bionics generated $48.0 million from the sale or maturity of investments in Q2 2026, more than offsetting $20.0 million of investment purchases and $1.0 million of capital expenditures.
  • Operating losses remain persistent. The company recorded a $23.4 million net loss in Q2 2026, compared with a $21.9 million loss in Q1 2026 and a $16.9 million loss in the restated Q2 2025 results.
  • Investment income provides some support but does not offset operating losses. Interest and investment income was $2.2 million in Q2 2026, helping reduce the pretax loss but representing only a small portion of the $25.6 million operating loss.
  • Operating expenses are growing faster than gross profit. Total operating expenses rose to $44.5 million in Q2 2026 from $40.7 million in Q1 2026 and $32.4 million in Q2 2025. Marketing expense was particularly high at $24.6 million, or roughly 77% of quarterly revenue.
  • Cash generation has not yet become self-sustaining. Operating cash flow was negative in every reported quarter provided, including $14.6 million of use in Q2 2026. Continued losses could reduce the company’s liquid investment balances over time.
  • Share dilution is a material risk. Weighted-average basic shares increased from 30.7 million in Q1 2025 to 44.5 million in Q2 2026. The increase in common stock and the $2.4 million of equity issuance in Q2 2026 indicate that future financing could further dilute existing shareholders.

The balance sheet is currently a stabilizing factor: current assets of $231.0 million substantially exceeded current liabilities of $26.0 million, and debt-related obligations were limited primarily to $4.9 million of capital lease liabilities. However, total assets declined from $330.0 million in Q2 2025 to $292.4 million in Q2 2026, while retained earnings fell further to a deficit of $415.2 million.

For investors, the central question is whether Beta Bionics can convert its improving revenue and gross margins into lower operating losses. Until marketing and other operating expenses become more disciplined, the company’s attractive liquidity position may continue to fund expansion rather than shareholder returns.

10/10/26 01:51 AM ETAI Generated. May Contain Errors.

Beta Bionics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Beta Bionics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Beta Bionics' net income appears to be on a downward trend, with a most recent value of -$73.20 million in 2025, falling from -$44.10 million in 2023. The previous period was -$54.76 million in 2024. View Beta Bionics' forecast to see where analysts expect Beta Bionics to go next.

Beta Bionics' total operating income in 2025 was -$71.68 million, based on the following breakdown:
  • Total Gross Profit: $55.54 million
  • Total Operating Expenses: $127.22 million

Over the last 2 years, Beta Bionics' total revenue changed from $12.00 million in 2023 to $100.25 million in 2025, a change of 735.8%.

In the past 5 quarters, Beta Bionics' cash and equivalents has ranged from $30.21 million in Q1 2026 to $44.32 million in Q2 2026, and is currently $44.32 million as of their latest financial filing in Q2 2026.

Beta Bionics had total debt of $5.37 million at the end of 2025, a 6.3% decrease from 2024, and a 78.9% increase since 2023.

Over the last 2 years, Beta Bionics' book value per share changed from -38.30 in 2023 to 6.53 in 2025.


Related Companies

Financial statements for NASDAQ:BBNX last updated on 7/29/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Look at Elon’s face after meeting with China
Elon Musk recently met with Chinese President Xi Jinping, and a former Wall Street Journal Personal Finance Ex...
International Living | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel